Reducing pain caused as a side effect of vincristine chemotherapy
Can we reduce or eliminate the sensory nerve damage caused by vincristine chemotherapy? Potential novel adjunct neuroprotective/analgesic therapies.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Can we reduce or eliminate the sensory nerve damage caused by vincristine chemotherapy? Potential novel adjunct neuroprotective/analgesic therapies.
Towards inhibiting cut-and-run: An aberrant V(D)J recombination reaction that leads to lymphoid cancers
Targeting refractory and dormant stem cells in childhood leukaemia
Understanding and improving the mechanism of action of anti-GD2 monoclonal antibody therapy in neuroblastoma
Exploring alterations in amino acid metabolism as novel therapeutic targets in paediatric glial tumours using advanced metabolomics methods
Understanding and therapeutically exploiting clonal evolution in chemo-resistant acute lymphoblastic leukaemia
Deep learning: An integrated approach to define clinical significance to components of the tumour microenvironment of rhabdomyosarcomas
Improving prediction of relapse, treatment delivery and outcomes for children with renal tumours in the UK
RNA helicase DDX3X regulates JAK-STAT signalling in acute lymphoblastic leukaemia